drugset / Trial / NCT06115642
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.
Timeline
- Start
- 2023-11-24
- Primary completion
- 2026-06-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | — | Intravenous |
| Background | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |